204 related articles for article (PubMed ID: 27069354)
1. Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years.
Farah Z; Ali S; Price-Kuehne F; Mackworth-Young CG
Biologics; 2016; 10():59-66. PubMed ID: 27069354
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
Abdulkader OAF; Qushmaq K; Aljishi F
Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice.
Pappas DA; Etzel CJ; Zlotnick S; Best J; Blachley T; Kremer JM
Rheumatol Ther; 2019 Sep; 6(3):421-433. PubMed ID: 31240499
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry.
Pappas DA; Blachley T; Zlotnick S; Best J; Emeanuru K; Kremer JM
Rheumatol Ther; 2020 Jun; 7(2):357-369. PubMed ID: 32232740
[TBL] [Abstract][Full Text] [Related]
6. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis.
Soubrier M; Pei J; Durand F; Gullestad L; John A
Rheumatol Ther; 2017 Jun; 4(1):133-149. PubMed ID: 27900570
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.
Ogata A; Hirano T; Hishitani Y; Tanaka T
Clin Med Insights Arthritis Musculoskelet Disord; 2012; 5():27-42. PubMed ID: 22438671
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P;
Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890
[TBL] [Abstract][Full Text] [Related]
11. Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review.
Besada E
Patient Prefer Adherence; 2014; 8():1051-9. PubMed ID: 25120354
[TBL] [Abstract][Full Text] [Related]
12. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
13. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
14. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
Kivitz A; Olech E; Borofsky MA; Zazueta B; Navarro-Sarabia F; Radominski SC; Merrill JT; Pacheco-Tena C; Pei J; Nasmyth-Miller C; Pope JE
J Rheumatol; 2018 Apr; 45(4):456-464. PubMed ID: 29247149
[TBL] [Abstract][Full Text] [Related]
15. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.
Navarro G; Taroumian S; Barroso N; Duan L; Furst D
Semin Arthritis Rheum; 2014 Feb; 43(4):458-69. PubMed ID: 24262929
[TBL] [Abstract][Full Text] [Related]
17. Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia.
An Q; Ma R; Yuan D; Huang J; Luo J; Wang Y; Pan Y; Wang P; Lv X; Pu D; He L
Clin Rheumatol; 2024 May; 43(5):1491-1501. PubMed ID: 38494557
[TBL] [Abstract][Full Text] [Related]
18. Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review.
Al-Shakarchi I; Gullick NJ; Scott DL
Patient Prefer Adherence; 2013; 7():653-66. PubMed ID: 23869169
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
20. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial.
Sanmarti R; Veale DJ; Martin-Mola E; Escudero-Contreras A; González C; Ercole L; Alonso R; Fonseca JE;
Arthritis Rheumatol; 2019 Oct; 71(10):1616-1625. PubMed ID: 31087542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]